BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...

FDA announces Eli Lilly's Tirzepatide is no longer in shortage in the US. Impact on compounded GLP-1s & semaglutide supply.

NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...